Search research articles
Contact Us
Filters
Showing results (1-10 of 16) with videos related to
Page
of 2
Sort By:
Conservation Biology : the Journal of the Society for Conservation Biology
|
June 15, 2022
Conservation Genetics of Freshwater Mussels: Comments on Mulvey et al
David J Berg, Paul H Berg
Neurology
|
November 18, 2018
Lasmiditan is an effective acute treatment for migraine: A phase 3 randomized study
Bernice Kuca, Stephen D Silberstein, Linda Wietecha, et al.
The Journal of Clinical Psychiatry
|
August 21, 2003
An integrated analysis of acute treatment-emergent extrapyramidal syndrome in patients with schizophrenia during olanzapine clinical trials: comparisons with placebo, haloperidol, risperidone, or clozapine
Christopher D Carlson, Patrizia A Cavazzoni, Paul H Berg, et al.
Journal of Clinical Pharmacology
|
November 21, 2019
Abuse Potential of Lasmiditan: A Phase 1 Randomized, Placebo- and Alprazolam-Controlled Crossover Study
Darren Wilbraham, Paul H Berg, Max Tsai, et al.
Headache
|
January 17, 2020
Issues Impacting Adverse Event Frequency and Severity: Differences Between Randomized Phase 2 and Phase 3 Clinical Trials for Lasmiditan
David Kudrow, John H Krege, Hans P Hundemer, et al.
Human Psychopharmacology
|
May 26, 2020
Effects of lasmiditan on simulated driving performance: Results of two randomized, blinded, crossover studies with placebo and active controls
Eric M Pearlman, Darren Wilbraham, Ellen B Dennehy, et al.
The Journal of Clinical Psychiatry
|
January 24, 2006
Comparison of treatment-emergent extrapyramidal symptoms in patients with bipolar mania or schizophrenia during olanzapine clinical trials
Patrizia A Cavazzoni, Paul H Berg, Ludmila A Kryzhanovskaya, et al.
The Journal of Headache and Pain
|
August 30, 2019
Lasmiditan for acute treatment of migraine in patients with cardiovascular risk factors: post-hoc analysis of pooled results from 2 randomized, double-blind, placebo-controlled, phase 3 trials
Robert E Shapiro, Helen M Hochstetler, Ellen B Dennehy, et al.
Expert Opinion on Drug Safety
|
October 19, 2006
Clinical safety of the selective PKC-beta inhibitor, ruboxistaurin
Janet B McGill, George L King, Paul H Berg, et al.
Investigative Ophthalmology & Visual Science
|
February 14, 2013
The effect of the oral PKC β inhibitor ruboxistaurin on vision loss in two phase 3 studies
Matthew J Sheetz, Lloyd Paul Aiello, Matthew D Davis, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 16) with videos related to
Sort By:
Page
of 2
Conservation Biology : the Journal of the Society for Conservation Biology
|
June 15, 2022
Conservation Genetics of Freshwater Mussels: Comments on Mulvey et al
David J Berg, Paul H Berg
Neurology
|
November 18, 2018
Lasmiditan is an effective acute treatment for migraine: A phase 3 randomized study
Bernice Kuca, Stephen D Silberstein, Linda Wietecha, et al.
The Journal of Clinical Psychiatry
|
August 21, 2003
An integrated analysis of acute treatment-emergent extrapyramidal syndrome in patients with schizophrenia during olanzapine clinical trials: comparisons with placebo, haloperidol, risperidone, or clozapine
Christopher D Carlson, Patrizia A Cavazzoni, Paul H Berg, et al.
Journal of Clinical Pharmacology
|
November 21, 2019
Abuse Potential of Lasmiditan: A Phase 1 Randomized, Placebo- and Alprazolam-Controlled Crossover Study
Darren Wilbraham, Paul H Berg, Max Tsai, et al.
Headache
|
January 17, 2020
Issues Impacting Adverse Event Frequency and Severity: Differences Between Randomized Phase 2 and Phase 3 Clinical Trials for Lasmiditan
David Kudrow, John H Krege, Hans P Hundemer, et al.
Human Psychopharmacology
|
May 26, 2020
Effects of lasmiditan on simulated driving performance: Results of two randomized, blinded, crossover studies with placebo and active controls
Eric M Pearlman, Darren Wilbraham, Ellen B Dennehy, et al.
The Journal of Clinical Psychiatry
|
January 24, 2006
Comparison of treatment-emergent extrapyramidal symptoms in patients with bipolar mania or schizophrenia during olanzapine clinical trials
Patrizia A Cavazzoni, Paul H Berg, Ludmila A Kryzhanovskaya, et al.
The Journal of Headache and Pain
|
August 30, 2019
Lasmiditan for acute treatment of migraine in patients with cardiovascular risk factors: post-hoc analysis of pooled results from 2 randomized, double-blind, placebo-controlled, phase 3 trials
Robert E Shapiro, Helen M Hochstetler, Ellen B Dennehy, et al.
Expert Opinion on Drug Safety
|
October 19, 2006
Clinical safety of the selective PKC-beta inhibitor, ruboxistaurin
Janet B McGill, George L King, Paul H Berg, et al.
Investigative Ophthalmology & Visual Science
|
February 14, 2013
The effect of the oral PKC β inhibitor ruboxistaurin on vision loss in two phase 3 studies
Matthew J Sheetz, Lloyd Paul Aiello, Matthew D Davis, et al.
Page
of 2